Olema Pharmaceuticals, Inc. stock is down -7.69% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 December’s closed higher than November. In the last 6 Unusual Options Trades, there were 6 CALLs.
|Date & Time||Expiration Date||Strike Price||Trade Type||Size||Open Interest|
|03 Oct 15:34||19 Jan, 2024||12.50||1007|
|03 Oct 16:01||19 Jan, 2024||12.50||1007|
|18 Oct 19:48||19 Jan, 2024||10.00||218|
|19 Oct 17:48||19 Jan, 2024||10.00||459|
|19 Oct 18:40||19 Jan, 2024||10.00||459|
|21 Nov 17:06||19 Jan, 2024||15.00||54|
Olema Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies for women's cancers. OP-1250, an estrogen receptor antagonist and a selective ER degrader, is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.